Introduction
Zonisamide (ZNS) is a sulphonamide antiepileptic drug (AED) used to treat epilepsy around the world. 1 Recent studies suggested that ZNS is an effective treatment for motor and nonmotor symptoms of Parkinson's disease (PD) (for a review 2 ). However, only one randomized, double-blind, multicentre, placebo-controlled study conducted in Japan 3 demonstrated the efficacy of ZNS as add-on administration in treating motor symptoms in PD patients, and most observations relating to the effectiveness of ZNS for PD symptoms have been made in Japan, where the drug was originally synthesized and released in March 2009 as an antiparkinsonian agent.
Here we report the case of a Caucasian 78 year-old male patient with longstanding PD and dementia, who came to our attention because he developed nocturnal seizures; ZNS treatment significantly improved both his epilepsy and PD, without affecting cognitive functions.
Methods
The patient was diagnosed with PD ten years before his presentation with seizures. At first, he had complained of resting tremor of the right hand, but later he had gradually worsening extrapyramidal symptoms with bradykinesia, dysarthria, hypomimia, hyposmia and a camptocormic posture when walking. He was initially treated with pramipexole, which was titrated up to a dosage of 2.1 mg/day. After one year levodopa was added and gradually increased to a dosage of 800 mg/day without fully controlling his PD symptoms. Moreover, in the last four years prior to presentation with seizures, he showed progressive cognitive impairment with memory deficits as well as moderate temporal and spatial disorientation. For this reason he had been started on rivastigmine 6 mg/day three years prior to the onset of his seizures. The patient was referred with a history of two tonicclonic seizures, which had been observed by his wife. The second of these seizures had happened two weeks after the first. Both episodes occurred from sleep, lasted 2 min and were followed by confusion for about 10 min. There were no apparent precipitants (i.e. fever, illness, alcohol or use of proconvulsant drugs). The patient did not have a family or personal history of epilepsy or seizures.
Neurological examination on admission to our department showed a mild-to-moderate extrapyramidal syndrome. The motor impairment had started significantly to interfere with the patient's everyday life. He was increasingly dependent on family members for dressing and bathing, had stopped cycling, and was unable to pursue his hobbies. For these reasons he got depressed. The patient did not experience ''on'' and/or ''off'' periods. The unified Parkinson's disease rating scale (UPDRS) Part III score (assessment of motor function) -1 h after administration of 200 mg levodopawas 36 (Table 1 ). In addition, there were significant impairments in UPDRS Part I (evaluation of mentation/cognition, behavior and mood -score: 6) and Part II scores (self-evaluation of activities of daily living -score 13, see Table 1 ). Neuropsychological evaluation confirmed slight cognitive impairment in several domains: mild episodic memory deficits and more severe difficulties with attention, programming, logical reasoning and language. The patient also showed slowing of cognitive processing speed. The cognitive pattern was suggestive of a PD-related dementia. The Mini Mental State Examination (MMSE) score was 22. Brain MRI showed a mild chronic vascular leukoencephalopathy with cortical atrophy. Finally, 24-h EEG monitoring revealed interictal epileptiform abnormalities in the left frontotemporal regions during NREM sleep. During wakefulness, the EEG showed a mild slowing of background activity. After this evaluation ZNS was added to the previously prescribed antiparkinsonian medication at a dosage of 25 mg twice daily, and slowly titrated up to 100 mg twice daily. At one-month follow-up the patient was seizure-free without any adverse effects and demonstrated a clear improvement of his extrapyramidal symptoms on neurological examination, especially in terms of tremor and bradykinesia (UPDRS Part III = 24). The improvement was clinically significant: the patient regained his independence in everyday life and recovered his interests, such as cycling and gardening; his mood also improved (UPDRS Part I = 2; UPDRS Part I = 9; Table 1 ). This improvement was maintained at six months and one-year follow-up (Table 1) without any changes of his anti-PD drugs. The patient's cognitive status also remained stable (Table 1) .
Discussion
This observation offers support for the efficacy of ZNS -a wellknown antiepileptic drug -as a treatment for motor and nonmotor symptoms of PD in a Caucasian man, as already described by Japanese authors.
2-4 Moreover, we describe the first use of ZNS in a patient with PD dementia. As previously suggested, 3-7 the main improvements were noted in terms of tremor and bradykinesia. However, these improvements had a significant effect on our patient's general behavior, mood and self-sufficiency in performing activities of daily living. The pharmacological mechanisms explaining ZNS's beneficial effects in PD are unclear, and both dopaminergic and nondopaminergic mechanisms seem to be involved. In particular, data coming from animal studies demonstrates that ZNS has a biphasic effect on the dopaminergic system: therapeutic doses of the drug increase intracellular and extracellular dopamine in the rat striatum, while supratherapeutic doses reduce intracellular dopamine. 8 Moreover, ZNS blocks T-type calcium channels and inhibits MAO-B, 2 but these effects do not seem to be the main mode of action. In our case low doses of ZNS led to seizure control as well as an improvement of PD symptoms. The improvement of parkinsonian symptoms was maintained after six months and one-year follow-up, whilst cognition remained stable. It is conceivable that the latter observation was related to the neuroprotective properties of ZNS, clearly documented in several experimental studies in animals. [9] [10] Having said that, it is possible that the arrest of cognitive decline was due to the improvement of the patient's mood: ZNS has a serotonergic effect that seems to be associated with improvements in bipolar depression.
11
It is possible that the involvement of the cerebral cortex in the patient's neurodegenerative process explained the occurrence of seizures in our case, as leukoencephalopathy was mild and mostly affected subcortical regions. In fact, there was no clear correlation between the interictal EEG focus localized in the left mesiotemporal regions and the ischemic lesions detected on brain MRI. PD has consistently been found to be associated eventually with cortical damage, beginning in the anteromedial temporal mesocortex. 12 ZNS treatment was well tolerated in our patient without affecting cognitive functions or triggering behavioral or psychological symptoms. While PD occurs about three times more often in patients with epilepsy, 13 surprisingly there are no studies on the efficacy and tolerability of AEDs in these patients. Indeed different AEDs, such as carbamazepine, phenytoin and tiagabine, have been associated with movement disorders, mainly dystonic reactions 14 or athetosis 15 ; in particular, valproate is widely known to induce tremor. 14 In keeping with our observation, a low dose of ZNS has recently been used with benefit and without adverse effects to treat parkinsonism in a few cases of dementia with Lewy bodies, associated with psychotic and behavioral symptoms. 16, 17 In conclusion, we propose that low dose ZNS could be an optimal and well-tolerated choice for the treatment of seizures in patients affected by PD, even when dementia coexists; other AEDs, in particular valproate, should be avoided in these patients as it may worsen their extrapyramidal symptoms. The Mini Mental State Examination (MMSE) and the unified Parkinson's disease rating scale (UPDRS) were performed in the morning 1 h after administration of 200 mg levodopa.
